TGF-β inhibitors have been extensively studied in both preclinical and clinical settings for their potential to alleviate renal fibrosis, improving renal function, and decreasing proteinuria in various CKD models, including UUO (Moon et al. 2006) and DKD (Benigni et al. 2006). This evidence concerns the gene TGFB1 and renal fibrosis.